HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization
about
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of CardiologyInteraction of Hydrogen Sulfide with Nitric Oxide in the Cardiovascular SystemAbnormal Ca(2+) cycling in failing ventricular myocytes: role of NOS1-mediated nitroso-redox balanceNitroxyl (HNO): A novel approach for the acute treatment of heart failureSoluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse.New acyloxy nitroso compounds with improved water solubility and nitroxyl (HNO) release kinetics and inhibitors of platelet aggregationDisulfide-activated protein kinase G Iα regulates cardiac diastolic relaxation and fine-tunes the Frank-Starling response.Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.Nitroxyl (HNO) for treatment of acute heart failure.Tri-modal regulation of cardiac muscle relaxation; intracellular calcium decline, thin filament deactivation, and cross-bridge cycling kinetics.A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure.The chemical biology of HNO signaling.Resveratrol protects against lipopolysaccharide-induced cardiac dysfunction by enhancing SERCA2a activity through promoting the phospholamban oligomerization.Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat.Meeting report of the 8th International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017.Role of protein phosphorylation in excitation-contraction coupling in taurine deficient hearts.Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure
P2860
Q26765793-8B2105CA-5220-4676-8A38-597431AF61D0Q26774063-1C8A50AD-1467-4E35-9DD6-2F8C3F965325Q26852587-BC7D19C2-051F-451C-92FD-C60AA15E689BQ33946688-2E24B0D8-EB15-43E3-A4FB-BAD037FAB09CQ34892722-7CE86FCC-CDF8-4D6A-956C-92DC64134619Q36011399-029579B5-8BB4-4CB6-B07B-61CEFD0F4A6DQ37393164-EFE7C2E5-62B9-4D0A-93E3-6C346F310781Q38208442-12B279AB-590D-41BD-BE51-D01F9EBFAB44Q38224809-B75025AE-2036-439E-B0F3-3146B3685C25Q38284950-8746750D-D038-4537-AC39-9546A0B59CC4Q38693298-58A5C3BE-566C-4E8E-9431-2E195CE552B5Q38827338-FC52CA16-1FA1-4C2D-972A-A1623948227DQ38935734-EFAAB819-7AE1-4E50-890F-042009277E1CQ39426145-43250ACA-E0AA-4229-A3BA-518DB3A29BADQ41025346-C53331BF-BF06-4B7A-A813-FBC769045B9AQ47156125-CDF92B8A-AE84-4AB1-83E8-A42C03C6405CQ47904506-1F696817-FB4D-4855-B805-582A6C2AB582Q55069898-251225CB-65AC-4931-9626-25F86DC4FCFFQ59129621-2EF2EBAE-4DE2-4ADC-9D3D-3BFCE0BDEC81
P2860
HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HNO enhances SERCA2a activity ...... phospholamban oligomerization
@en
HNO enhances SERCA2a activity ...... phospholamban oligomerization.
@nl
type
label
HNO enhances SERCA2a activity ...... phospholamban oligomerization
@en
HNO enhances SERCA2a activity ...... phospholamban oligomerization.
@nl
prefLabel
HNO enhances SERCA2a activity ...... phospholamban oligomerization
@en
HNO enhances SERCA2a activity ...... phospholamban oligomerization.
@nl
P2093
P2860
P356
P1476
HNO enhances SERCA2a activity ...... phospholamban oligomerization
@en
P2093
Brian A Stanley
Brian O'Rourke
Carlo G Tocchetti
David A Kass
Dong I Lee
Evangelia G Kranias
Gerald M Wilson
Gizem Keceli
James E Mahaney
Jeff D Ballin
P2860
P304
P356
10.1089/ARS.2012.5057
P577
2013-10-01T00:00:00Z